A Phase II Trial of Ethyol (Amifostine) in Adult Patients With Advanced Myelodysplastic Syndromes
OBJECTIVES: I. Determine the overall hematologic response rate to amifostine in patients
with advanced myelodysplastic syndrome. II. Determine the toxic effects of amifostine in
OUTLINE: This is an open label study. Patients receive intravenous amifostine over 15
minutes three times a week. Patients failing to respond by 8 weeks undergo dose escalation.
Nonresponding patients are removed from the study by 12 weeks. Therapy is continued for up
to six months in responding patients. Patients are observed for duration of response upon
therapy discontinuation. Patients who relapse will have therapy resumed at the previous
dose. Patients will be followed until death.
PROJECTED ACCRUAL: A maximum of 36 patients will be accrued.
Primary Purpose: Treatment
Howard R. Terebelo, DO
Providence Cancer Institute at Providence Hospital - Southfield Campus
United States: Federal Government
|Barbara Ann Karmanos Cancer Institute
|Detroit, Michigan 48201
|Cleveland Clinic Cancer Center
|Cleveland, Ohio 44195
|Henry Ford Hospital
|Detroit, Michigan 48202
|Marquette General Hospital
|Marquette, Michigan 49855
|Osteopathic Medical Oncology and Hematology, P.C.
|Clinton Township, Michigan 48038-1657
|Garden City Hospital
|Garden City, Michigan 48135
|Providence Hospital Cancer Center
|Southfield, Michigan 48075